Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23685819 | 0.88 | TRPA1 (0.39) | TRPA1IDO1AXLNOS1ESR1 | |
| SCHEMBL20618762 | 0.83 | TRPA1 (0.44) | TRPA1IDO1AXLNOS1METAP2 | |
| SCHEMBL24094124 | 0.81 | NOS1 (0.41) | TRPA1IDO1AXLNOS1ESR1 | |
| SCHEMBL21540839 | 0.78 | IDO1 (0.54) | IDO1AXLNOS1METAP2TSHR | |
| SCHEMBL24368019 | 0.78 | IDO1 (0.54) | IDO1AXLNOS1METAP2TSHR | |
| SCHEMBL23685818 | 0.73 | TRPA1 (0.44) | TRPA1IDO1AXLNOS1ESR1 | |
| SCHEMBL25581727 | 0.72 | TSHR (0.36) | TSHR | |
| SCHEMBL26714988 | 0.72 | AXL (0.49) | TRPA1AXLESR1ESR2CDK2 | |
| SCHEMBL21217948 | 0.71 | TRPA1 (0.39) | TRPA1IDO1AXLNOS1ESR1 | |
| SCHEMBL24969371 | 0.71 | ESR2 (0.36) | IDO1AXLNOS1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046700-B2 | Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis | MERCK PATENT GMBH (DE) | 2021-06-29 | — | — | US | disclosed |
| US-20200123158-A1 | NOVEL COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | SALVENSIS (GB) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046700-B2 | Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis | P2RY1, P2RX5, TPMT | TRPA1 1075/4885IDO1 90/4885AXL 1180/4885 |
| US-20200123158-A1 | NOVEL COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | SI, SLC10A2, ALPI | TRPA1 1530/4885IDO1 345/4885AXL 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.